GLP-1 medicines are reshaping diabetes and weight-loss care, driving a race for customers, capital and market share. The SANOR GLP-1 Market Monitor tracks the companies, deals and commercial developments shaping this market.
Updated 23 September 2026
Annual global market size · 2025
Forecast annual growth (CAGR) · 2025–2035
Last 12 months
Last 12 months
Lilly says U.S. regulators have expanded Mounjaro’s approved uses to include reducing cardiovascular risks in high-risk adults with type 2 diabetes. Mounjaro was already approved for blood-sugar control.
Eli LillyLilly reports lower medical spending among older adults using its weight-loss injection Zepbound. The estimates exclude the medicine’s price and cannot establish that treatment caused the difference.
Eli LillyGenentech, part of Roche, will pay Hanmi $190 million initially for rights to develop and sell Hanmi’s experimental obesity medicine outside South Korea. Further payments depend on progress and sales.
Hims & Hers reported rising sales and subscriber numbers alongside a quarterly loss. The online healthcare provider’s figures include weight-management services as well as other areas of care.
Hims & HersLilly says demand for Mounjaro and Zepbound helped lift quarterly sales to $23 billion. Both medicines contain tirzepatide, sold under different brands for diabetes and weight management.
Eli LillyNovo Nordisk now expects a smaller decline in annual sales, citing improved expectations for diabetes and weight-loss medicines. The revised forecast still ranges from a 6% fall to no growth.
Novo NordiskInvestors will provide Poolbeg with £3.5 million in exchange for new shares. Poolbeg says the money will help fund trials of a GLP-1 obesity treatment taken by mouth and a separate cancer-support medicine.
Poolbeg PharmaHims & Hers says it has bought Eucalyptus, adding an established digital healthcare business in several overseas markets. Payments for the acquisition can total up to $1.15 billion, subject to conditions and adjustments.
Hims & HersThe FDA proposed restricting a route certain facilities use to prepare compounded GLP-1 medicines from raw ingredients. The April announcement was a proposal for consultation, not a withdrawal of approved medicines.
Lilly announced an expanded role for Daniel Skovronsky as chief scientific and product officer, overseeing research and development alongside launches and product strategy in cardiometabolic health, immunology and neuroscience. He continues to report to chair and CEO David Ricks.
Eli LillyGrow revenue at each location and build a commercial model that can scale across a clinic group.
Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.
SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.
SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.
All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.
